---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000351"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:47:54.614916+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Corbus receives Nasdaq delisting notice for bid price non-compliance; hearing requested

## Summary
- Nasdaq Staff determined to delist CRBP for failure to maintain $1.00 minimum bid price; company will request hearing to stay suspension.
- Stockholders approved reverse stock split (1:4 to 1:40) on Dec 20, 2022; board to set exact ratio to potentially regain compliance.
- Previous 180-day compliance period ended Jan 3, 2023 without cure; company had transferred to Nasdaq Capital Market in July 2022.
- If delisted, trading liquidity, financing ability, and investor confidence could be adversely affected.

## SEC filing metadata
- accession: 0000950170-23-000351
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017023000351/0000950170-23-000351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017023000351/crbp-20230104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000351
- JSON: https://secwatch.observer/filing/0000950170-23-000351.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000351.txt

## Key facts
- Listing & Compliance Notices
  Corbus Pharmaceuticals Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 4, 2023, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s continued non-compliance with the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000095017023000351/0000950170-23-000351-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.